Latest News

CARLTON, Mercer County — Kyle Bennett is a 4-year-old, and he looks and behaves as such. It’s all shy smiles at first, then he opens up to show you what he’s into — kid stuff like his puppy, fishing with Dad, games, Scooby Doo … and more Scooby Doo. Kyle...
COPENHAGEN, Denmark — Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of...
Gothenburg, Sweden – Children with cystic fibrosis (CF) who were treated with Kaftrio (elexacaftor/tezacaftor/ivacaftor) maintained stable lung function over one year after reducing the frequency of hypertonic saline and other airway-clearance treatments, according to a prospective multicentre study. The reduction in treatment frequency was also associated with fewer days of...
Washington, DC — Children’s National Hospital and the Gilbert Family Foundation today announced a new $8 million, five-year grant to support groundbreaking research on neurofibromatosis type 1 (NF1). The grant, which is part of Gilbert Family Foundation’s Brain Tumor Initiative (BTI), will accelerate investigations aimed at improving the lives of...
INGELHEIM am RHEIN, Germany – China’s National Medical Products Administration (NMPA) has approved JASCAYD® (nerandomilast) as the first new treatment for adults with progressive pulmonary fibrosis (PPF) in more than five years, marking a breakthrough for millions affected by the life-threatening lung condition.4 The approval, based on the largest clinical trial program in PPF...
PARIS, France – The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura. These approvals mark another step in Sanofi’s long-term commitment to China, reinforcing the company’s ambition to bring...
BEIJING, China — Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of...